Lenvima (lenvatinib) — CareFirst (Caremark)
Hepatocellular carcinoma
Initial criteria
- Used as a single agent
- AND Member has unresectable disease and is not a transplant candidate
- OR Member has extrahepatic/metastatic disease and is ineligible for resection, transplant, or locoregional therapy
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
12 months